• Summary:

    Xuan Wang holds a Ph.D. (Dr. sc.) title from ETH Zürich (Institute of Biochemistry) awarded in 2015. She joined the Caflisch group in May 2016 as a postdoctoral researcher.

    Xuan is an experienced and motivated cell biologist and pharmacologist with in vitro and in vivo research experience. Her responsibilities include proof-of-principle studies to explore new therapeutic applications for bromodomain compounds discovered in-house, and for compound validation works such as assessing target engagement, toxicity and metabolic stability.

    LinkedIn

    Dr. Xuan Wang was a member of the Caflisch group from 05/2016 - 02/2019.

(2022)

  1. Nai, F., Nachawati, R., Zálešák, F., Wang, X., Li, Y., Caflisch, A. ACS Med. Chem. Lett. 13 (9) 1500-1509 (2022) DOI | Full Text | Supp Info

(2018)

  1. Batiste, L., Unzue, A., Dolbois, A., Hassler, F., Wang, X., Deerain, N., Zhu, J., Spiliotopoulos, D., Nevado, C., Caflisch, A. ACS Cent. Sci. 4 180-188 (2018) DOI | Full Text | Supp Info


If you find errors such as broken or incorrect links, typos, etc., we would be most grateful if you could notify us of these errors.

Note to publishers: If you find that a file is hosted here that violates the respective Copyright agreement, please notify us immediately so it can be removed. We have heeded the agreement to the best of our knowledge.